Schroeder continued, “while our commercialization efforts for XENLETA have faced significant headwinds due to the global pandemic, we remain focused on maximizing the value of this novel, first-in-class antibacterial agent in the U.S. through our focused commercial investments, and outside the U.S. by expanding our partnerships globally. like those incorporated in the International Quality Plasma Program (IQPP) are. Program Description IQPP certified centers provide manufacturers with the highest quality source material. “We had a strong close to 2021 for SIVEXTRO, which contributed to extending our cash runway well into the fourth quarter of 2022 and we continue to propel the product back to historical prescription trends through our promotional efforts.” Mr. Plasma Protein Therapeutics Association top competitors are Intralytix. IQPP provides independent, third-party evaluation and recognition of a center's adherence to global industry standards for source plasma. “We made excellent progress in 2021 in spite of the COVID pandemic and are poised for continued growth in 2022,” commented Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. DUBLIN, Ireland and FORT WASHINGTON, PA – Janu(GLOBE NEWSWIRE) - Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced a business update today and preliminary, unaudited financial results for the fourth quarter of 2021.
0 Comments
Leave a Reply. |